T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation weiter
2026 “Jugend forscht” Berlin-Buch regional winners
From pond water probes to pesticide impact and chili-infused soil: 85 young researchers presented 43 projects at the “Jugend forscht” regional science competition at Campus Berlin-Buch. Under the theme “Maximum Perspective,” students tackled real-world challenges with curiosity and creativity. weiter
Eckert & Ziegler and UJF Significantly Increase Production Volume for Actinium-225
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”) have successfully transitioned their joint Actinium-225 initiative into larger scale manufacturing using the facilities in Řež and Braunschweig. weiter
scienceCLASH podcast funded for a second season
scienceCLASH, a podcast developed at the Gläsernes Labor, has won the MINT-EC School Award, which is sponsored by the Dr. Hans Riegel Foundation and comes with 7,000 euros in funding. A second season is already in the works – and researchers at the Max Delbrück Center are invited to participate. weiter
Pentixapharm publishes positive Phase II data on Pentixafor PET diagnostics
The study confirms PENTIXAFOR-PET as a non-invasive alternative to adrenal vein catheterization in primary aldosteronism weiter
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 weiter
Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
According to preliminary, unaudited figures for the 2025 financial year, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around € 312 million and adjusted EBIT of around € 78 million. Sales are up around 5% on the previous year, while adjusted EBIT is up by around 18%. Net profit (from continuing and discontinued operations), which is only reported here for comparison purposes, rose to around € 48 million (previous year: € 33.3 million). weiter
A fresh take on proteomics
Start-up company Absea Biotechnology GmbH is developing new proteomics technologies. An interview with Dr. Philip Lössl, Senior VP Science and Business Development weiter
Moving biomedical research to the market
Discovery, invention and spin-offs – Nevine Shalaby, Head of Innovation & Entrepreneurship was interviewed by “Buch Inside” about the path from research to innovation. She discusses how her team supports marketable research discoveries made at the Max Delbrück Center. weiter
Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement
Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in South Korea. Eckert & Ziegler will supply SK Biopharmaceuticals with Actinium-225 (Ac-225) to accelerate their research and development activities in radiopharmaceutical therapies. weiter
From bench to business
What does it take to turn Max Delbrück Center research into a startup? Meet Klaas Yperman, our very first Entrepreneur-in-Residence. Yperman has won a Helmholtz Enterprise grant to develop a roadmap for turning compounds discovered in the Lewin lab into a drug to treat neuropathic pain. weiter
Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales in the first nine months of 2025 by 4% to €224.1 million compared to the same period last year. EBIT before special items from continuing operations (adjusted EBIT) rose by 9% to €50.8 million. Net profit (from continuing and discontinued operations) grew by 28% to €29.9 million, or €0.48 per share. weiter
Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma
Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient has been dosed in the SANTANA-225 Phase 1/2 study of 225Ac-SSO110 for the treatment of extensive stage small cell lung cancer (ES-SCLC) and Merkle Cell Carcinoma (MCC). 225Ac-SSO110 is a potentially first- and best-in-class Actinium-225-labelled antagonist of the somatostatin type 2 receptor (SSTR2). SSTR2 is highly overexpressed in neuroendocrine tumors relative to healthy tissue, making it an ideal target for radioligand therapies (RLTs). weiter
T-knife Therapeutics Presents Preclinical Data
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting weiter
Gläsernes Labor: Peering at proteins
During project week “Expedition Proteins” at the Gläsernes Labor, students immerse themselves in protein research – isolating samples, loading gels and visiting a real structural biology lab. The week-long workshop gives them a hands-on glimpse into how scientists explore life’s molecular machinery. weiter
Sharks, microbes and a world premiere
Berlin Science Week 2025 kicks off on November 1. The Max Delbrück Center invites science enthusiasts to talks and tours, a concert, and exhibitions highlighting our research and to join discussions on a wide range of topics. weiter
Volker Haucke receives the Ernst Schering Prize 2025
The Ernst Schering Prize 2025, endowed with 50.000 euros, is awarded to Prof. Dr. Volker Haucke, Director at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Professor of Molecular Pharmacology at Freie Universität Berlin. This prestigious science award honors his groundbreaking discoveries on the function of signaling lipids, which control the cellular responses to messengers, hormones, and nutrients, thereby shaping central processes in cell communication. weiter
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, through Novartis Pharma K.K. which will oversee product distribution and safety information management as the Designated Marketing Authorization Holder for GalliaPharm® in Japan. weiter
Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price target of € 24.00. This corresponds to a price potential of 46.8% compared to the Xetra closing price of € 16.35 on 8 September 2025. weiter
Promoting awareness of health research
During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Center, Charité – Universitätsmedizin Berlin, the German Center for Child and Adolescent Health and others. weiter
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 clinical trial of ART-101 in the United States, with manufacturing to be performed at Eckert & Ziegler’s state-of-the-art GMP facility in Boston, MA. weiter
Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. weiter
Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite
The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply. weiter
Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023 and from 2023 to 2025. In addition to successfully fulfilling all mandatory criteria, Eckert & Ziegler also scored highly in the voluntary and excellence criteria thanks to its long-standing commitment to training. weiter
The Long Night of the Sciences 2025
The Long Night of the Sciences has been a Berlin tradition for 25 years – and the Max Delbrück Center and Campus Berlin-Buch have been part of it from the very beginning. On June 28, we celebrated this milestone with science enthusiasts, families, and special guests. weiter
Students from Freie Universität Berlin visited the Campus Berlin-Buch
Visiting the Campus Berlin-Buch: Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025. weiter
